Lyell Immunopharma, Inc. — Form 8-K
Filed November 4, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 22/100
What the filing says
Lyell Immunopharma filed an 8-K disclosing Item 3.02 (Unregistered Sales of Equity Securities) on November 4, 2026, covering events of November 3, 2026. The filing provides no substantive details: counterparty identity, share count, price per share, total transaction value, and specific use of proceeds are not disclosed in this summary. Full disclosure documents were not provided in the extracted text.
Why this rating
Unregistered equity sale is routine filing requirement but lacks material specifics (amount, terms unknown). Cannot assess impact on $129M market-cap company without transaction size.
Extracted items
See more from November 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.